Gliosarcoma Market Report 2026

The gliosarcoma market size has grown strongly in recent years. It will grow from $1.25 billion in 2025 to $1.32 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to limited clinical understanding, advances in neuro-pathology, growth of oncology research institutes, improved imaging technologies, academic research interest.

The gliosarcoma market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to increased rare cancer research funding, precision diagnostics development, improved treatment protocols, expansion of molecular testing, collaboration between research centers. Major trends in the forecast period include increased research into rare brain tumors, growing use of molecular diagnostics, expansion of multimodal treatment strategies, rising focus on tumor biology studies, improved diagnostic accuracy.

The rising incidence of brain tumors is expected to drive the growth of the gliosarcoma market in the coming years. Brain tumors are abnormal growths of cells in the brain that can be benign or malignant, often causing symptoms such as headaches, seizures, and vision disturbances. The increasing incidence of brain tumors is attributed to enhanced diagnostic technologies, greater awareness, and potential environmental and lifestyle factors that increase exposure to risk elements. Treatment for gliosarcoma is critical as it targets this rare and aggressive cancer, aiming to manage symptoms, extend survival, and improve patients’ quality of life. For instance, in February 2025, Dementia Australia, an Australia-based non-profit organization, reported that approximately 433,300 Australians are living with dementia, projected to rise to 812,500 by 2054. Younger-onset dementia affects around 29,000 people in 2025, expected to increase to 41,000 by 2054. Therefore, the rising incidence of brain tumors is driving the growth of the gliosarcoma market.

Leading companies in the gliosarcoma market are developing advanced technological solutions, such as wearable devices, to enable continuous, convenient monitoring of health and activity data, providing real-time insights and supporting patient engagement with treatment and wellness. Wearable devices are electronic gadgets designed to be worn on the body that track or enhance health, fitness, and daily activity. For example, in November 2024, Novocure Ltd., a UK-based oncology company, announced FDA approval for the use of Head Flexible Electrode (HFE) transducer arrays with Optune Gio for adult patients with glioblastoma multiforme (GBM). Optune Gio is a portable, wearable device that delivers tumor-treating fields (TTFields), applying physical forces to electrically charged portions of dividing cancer cells to inhibit rapid division. The new HFE arrays are 50% thinner and one-third lighter than the ceramic discs used in previous Optune Gio arrays due to their flexible polymer construction, improving comfort and usability for patients.

In October 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Modifi Biosciences for $1.3 billion. Through this acquisition, Merck aims to enhance its portfolio in glioblastoma and broader cancer therapies by advancing innovative treatments and expanding its oncology expertise. Modifi Biosciences is a US-based company focused on developing therapies for glioblastoma.

Major companies operating in the gliosarcoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Bio-Rad Laboratories Inc., Carl Zeiss AG, Elekta AB, Novocure Ltd., ImmunityBio Inc., Immatics Biotechnologies, Karyopharm Therapeutics Inc., Kintara Therapeutics Inc., Aveta Biomics Inc., Vigeo Therapeutics Inc.

North America was the largest region in the gliosarcoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gliosarcoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gliosarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gliosarcoma market by increasing costs of imported diagnostic equipment, molecular testing kits, and oncology drugs. Research institutes and hospitals are most affected due to dependence on imported technologies. These tariffs increase research costs by raising expenses for molecular diagnostics and investigational therapies. However, they support domestic diagnostic development, encouraging local innovation in rare brain tumor testing.

The gliosarcoma market research report is one of a series of new reports that provides gliosarcoma market statistics, including gliosarcoma industry global market size, regional shares, competitors with a gliosarcoma market share, detailed gliosarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the gliosarcoma industry. This gliosarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gliosarcoma is a rare and aggressive brain tumor composed of both glial and sarcomatous tissue, most commonly found in the cerebral hemisphere. It is used in research to study tumor biology and develop treatment strategies for glioblastoma and other brain cancers.

The main diagnostic methods for gliosarcoma include imaging techniques, histopathological examination, and biomarker testing. Imaging techniques are non-invasive methods, such as MRI, CT, and PET scans, that allow visualization of internal body structures to identify abnormalities. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. These treatments are utilized by hospitals, cancer research institutes, and specialty clinics.

The gliosarcoma market consists of revenues earned by entities by providing services such as molecular diagnostics, clinical trials and research, palliative care services, rehabilitation, and recovery support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gliosarcoma market also includes sales of diagnostic kits, research reagents, and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.